Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964616 | 0.86 | GLO1 (0.49) | ALDH1A1KMT2ALMNAHTTMEN1 | |
| SCHEMBL3025880 | 0.84 | FABP4 (0.52) | KEAP1NFE2L2ALDH1A1KMT2ATP53 | |
| SCHEMBL25450174 | 0.78 | KEAP1 (0.60) | KEAP1NFE2L2ALDH1A1KMT2ATP53 | |
| SCHEMBL30161175 | 0.78 | KEAP1 (0.60) | KEAP1NFE2L2ALDH1A1KMT2ATP53 | |
| SCHEMBL29335266 | 0.78 | FABP4 (0.50) | ALDH1A1KMT2ATP53LMNAMEN1 | |
| SCHEMBL14964574 | 0.77 | APP (0.58) | ALDH1A1KIT | |
| SCHEMBL3020516 | 0.77 | BRAF (0.49) | KMT2ALMNAMEN1PKMTSHR | |
| SCHEMBL30161802 | 0.76 | LMNA (0.59) | KEAP1NFE2L2ALDH1A1KMT2ATP53 | |
| SCHEMBL25450361 | 0.76 | LMNA (0.59) | KEAP1NFE2L2ALDH1A1KMT2ATP53 | |
| SCHEMBL25450191 | 0.76 | ALDH1A1 (0.57) | KEAP1NFE2L2ALDH1A1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | claimed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | claimed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | claimed |
| EP-2170830-B1 | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS | PLEXXIKON INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-06-13 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | disclosed |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-09-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2170830-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | KEAP1 2566/4885NFE2L2 2399/4885ALDH1A1 3328/4885 |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K11, MAP3K10 | KEAP1 1078/4885NFE2L2 1340/4885ALDH1A1 3137/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KEAP1 2328/4885NFE2L2 2878/4885ALDH1A1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.